Bert Rm Bammens

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3581782/publications.pdf

Version: 2024-02-01

130	7,378	47006	56724
papers	citations	47	83
		h-index	g-index

131	131	131	7641
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The emerging role of the apelinergic system in kidney physiology and disease. Nephrology Dialysis Transplantation, 2022, 37, 2314-2326.	0.7	8
2	Diagnostic Accuracy of Noninvasive Bone Turnover Markers in Renal Osteodystrophy. American Journal of Kidney Diseases, 2022, 79, 667-676.e1.	1.9	25
3	Natural History of Bone Disease following Kidney Transplantation. Journal of the American Society of Nephrology: JASN, 2022, 33, 638-652.	6.1	12
4	On Methods for the Measurement of the Apelin Receptor Ligand Apelin. Scientific Reports, 2022, 12, 7763.	3.3	4
5	MO011: The Use of a 4-Point Scoring Scale inÂ18F-FDG-PET/CT Imaging Helps for Diagnosis of Renal and Hepatic CYST Infections in Patients with Autosomal Dominant Polycystic Kidney Disease: A Validation Cohort. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
6	Enhanced MCP-1 Release in Early Autosomal Dominant Polycystic Kidney Disease. Kidney International Reports, 2021, 6, 1687-1698.	0.8	12
7	MO020AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE, CYTOPENIA AND POSTTRANSPLANT OUTCOMES: A RETROSPECTIVE ANALYSIS. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
8	Patterns of renal osteodystrophy 1â€‰year after kidney transplantation. Nephrology Dialysis Transplantation, 2021, 36, 2130-2139.	0.7	11
9	Static histomorphometry allows for a diagnosis of bone turnover in renal osteodystrophy in the absence of tetracycline labels. Bone, 2021, 152, 116066.	2.9	7
10	Cytopenia in autosomal dominant polycystic kidney disease (ADPKD): merely an association or a disease-related feature with prognostic implications?. Pediatric Nephrology, 2021, 36, 3505-3514.	1.7	1
11	AQP1 Promoter Variant, Water Transport, and Outcomes in Peritoneal Dialysis. New England Journal of Medicine, 2021, 385, 1570-1580.	27.0	34
12	Strategies for asymmetrical triacetate dialyser heparin-free effective haemodialysis: the SAFE study. CKJ: Clinical Kidney Journal, 2021, 14, 1901-1907.	2.9	10
13	Natural history of mineral metabolism, bone turnover and bone mineral density in de novo renal transplant recipients treated with a steroid minimization immunosuppressive protocol. Nephrology Dialysis Transplantation, 2020, 35, 697-705.	0.7	21
14	Discrepancies between bioimpedance spectroscopy devices in haemodialysis patients. CKJ: Clinical Kidney Journal, 2020, 13, 906-908.	2.9	1
15	P1064HEPARIN-FREE DIALYSIS: A PHASE II PILOT STUDY USING ASYMMETRIC TRIACETATE (ATA) CELLULOSE DIALYZERS. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
16	Measures of Loop Diuretic Efficiency and Prognosis in Chronic Kidney Disease. CardioRenal Medicine, 2020, 10, 402-414.	1.9	2
17	Sevelamer Use in End-Stage Kidney Disease (ESKD) Patients Associates with Poor Vitamin K Status and High Levels of Gut-Derived Uremic Toxins: A Drugâ€“Bug Interaction?. Toxins, 2020, 12, 351.	3.4	14
18	Implications of early diagnosis of autosomal dominant polycystic kidney disease: A post hoc analysis of the TEMPO 3:4 trial. Scientific Reports, 2020, 10, 4294.	3.3	2

#	Article	IF	Citations
19	Non-invasive Quantification of Fat Deposits in Skeletal Muscle Predicts Cardiovascular Outcome in Kidney Failure. Frontiers in Physiology, 2020, 11, 130.	2.8	10
20	Oxidative stress in chronic kidney disease. Pediatric Nephrology, 2019, 34, 975-991.	1.7	483
21	Oxidative stress in autosomal dominant polycystic kidney disease: player and/or early predictor for disease progression?. Pediatric Nephrology, 2019, 34, 993-1008.	1.7	25
22	A distinct bone phenotype in ADPKD patients with end-stage renal disease. Kidney International, 2019, 95, 412-419.	5.2	23
23	Persistent primary cytomegalovirus infection in a kidney transplant recipient: Multi-drug resistant and compartmentalized infection leading to graft loss. Antiviral Research, 2019, 168, 203-209.	4.1	8
24	Clinical courses and complications of young adults with Autosomal Recessive Polycystic Kidney Disease (ARPKD). Scientific Reports, 2019, 9, 7919.	3.3	50
25	Bone mineral density, bone turnover markers, andÂincident fractures in de novo kidney transplantÂrecipients. Kidney International, 2019, 95, 1461-1470.	5.2	61
26	3DUS as an alternative to MRI for measuring renal volume in children with autosomal dominant polycystic kidney disease. Pediatric Nephrology, 2018, 33, 827-835.	1.7	23
27	Unmet needs and challenges for follow-up and treatment of autosomal dominant polycystic kidney disease: the paediatric perspective. CKJ: Clinical Kidney Journal, 2018, 11, i14-i26.	2.9	16
28	Renal progression factors in young patients with tuberous sclerosis complex: a retrospective cohort study. Pediatric Nephrology, 2018, 33, 2085-2093.	1.7	29
29	Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease. New England Journal of Medicine, 2017, 377, 1930-1942.	27.0	420
30	Cliniciansâ€™ attitude towards family planning and timing of diagnosis in autosomal dominant polycystic kidney disease. PLoS ONE, 2017, 12, e0185779.	2.5	21
31	Decreased Circulating Sclerostin Levels in Renal Transplant Recipients With Persistent Hyperparathyroidism. Transplantation, 2016, 100, 2188-2193.	1.0	21
32	Cladophialophora bantiana osteomyelitis in a renal transplant patient. Medical Mycology Case Reports, 2016, 12, 17-20.	1.3	11
33	Phosphorus metabolism in peritoneal dialysis- and haemodialysis-treated patients. Nephrology Dialysis Transplantation, 2016, 31, 1508-1514.	0.7	32
34	The influence of renal transplantation on retained microbialâ€“human co-metabolites. Nephrology Dialysis Transplantation, 2016, 31, 1721-1729.	0.7	35
35	Proteinuria as a Noninvasive Marker for Renal Allograft Histology and Failure. Journal of the American Society of Nephrology: JASN, 2016, 27, 281-292.	6.1	65
36	Association of HO-1 (GT)n Promoter Polymorphism and Cardiovascular Disease: A Reanalysis of the Literature. Canadian Journal of Cardiology, 2016, 32, 160-168.	1.7	25

#	Article	IF	Citations
37	O085 : Lanreotide reduces liver volume yet accelerates muscle wasting and weight loss in symptomatic polycystic liver disease. Journal of Hepatology, 2015, 62, S232-S233.	3.7	0
38	The Effect of Anastomosis Time on Outcome in Recipients of Kidneys Donated After Brain Death: A Cohort Study. American Journal of Transplantation, 2015, 15, 2900-2907.	4.7	43
39	Purple Urine Bag Syndrome in Two Elderly Men with Urinary Tract Infection. Case Reports in Nephrology, 2015, 2015, 1-3.	0.4	5
40	FP594TARGETING MICROBIOTA DERIVED UREMIC RETENTION SOLUTES WITH ANTIBIOTICS. Nephrology Dialysis Transplantation, 2015, 30, iii271-iii271.	0.7	0
41	SP691THE SOLUBLE UROKINASE RECEPTOR (SUPAR) PREDICTS MORTALITY IN END-STAGE RENAL DISEASE. Nephrology Dialysis Transplantation, 2015, 30, iii607-iii607.	0.7	0
42	SP887LONG-TERM RENAL OUTCOME OF A LARGE COHORT OF PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX. Nephrology Dialysis Transplantation, 2015, 30, iii669-iii669.	0.7	0
43	Microscopic nephrocalcinosis in chronic kidney disease patients. Nephrology Dialysis Transplantation, 2015, 30, 843-848.	0.7	17
44	Invasive Aspergillosis After Kidney Transplant: Case-Control Study. Clinical Infectious Diseases, 2015, 60, 1505-1511.	5.8	38
45	O104 : Predictive model for the need for liver transplantation in symptomatic polycystic liver disease. Journal of Hepatology, 2015, 62, S245-S246.	3.7	0
46	Sclerostin Serum Levels and Vascular Calcification Progression in Prevalent Renal Transplant Recipients. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 4669-4676.	3.6	53
47	The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial. Lancet Diabetes and Endocrinology,the, 2015, 3, 687-696.	11.4	221
48	Soluble urokinase receptor is a biomarker of cardiovascular disease in chronic kidney disease. Kidney International, 2015, 87, 210-216.	5.2	52
49	Lanreotide Reduces Liver Volume, But Might Not Improve Muscle Wasting or Weight Loss, in Patients With Symptomatic Polycystic Liver Disease. Clinical Gastroenterology and Hepatology, 2015, 13, 2353-2359.e1.	4.4	29
50	How to isolate a patient with Cladophialophora bantiana infection? An opinion. Journal of Hospital Infection, 2015, 91, 89-90.	2.9	4
51	The Clinical Features of Trombotic Microangiopathies Post Transplantation.. Transplantation, 2014, 98, 532.	1.0	0
52	Serum Concentrations of p-Cresyl Sulfate and Indoxyl Sulfate, But Not Inflammatory Markers, Increase in Incident Peritoneal Dialysis Patients in Parallel with Loss of Residual Renal Function. Peritoneal Dialysis International, 2014, 34, 71-78.	2.3	34
53	Postimplantation X-ray parameters predict functional catheter problems in peritoneal dialysis. Kidney International, 2014, 86, 1001-1006.	5.2	13
54	The Histology of Kidney Transplant Failure. Transplantation, 2014, 98, 427-435.	1.0	124

#	Article	IF	Citations
55	The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis. Kidney International, 2014, 85, 636-640.	5.2	106
56	Development and validation of a polycystic liver disease complaint-specific assessment (POLCA). Journal of Hepatology, 2014, 61, 1143-1150.	3.7	27
57	Cardiovascular disease relates to intestinal uptake of p-cresol in patients with chronic kidney disease. BMC Nephrology, 2014, 15, 87.	1.8	48
58	Time course of asymmetric dimethylarginine and symmetric dimethylarginine levels after successful renal transplantation. Nephrology Dialysis Transplantation, 2014, 29, 1965-1972.	0.7	10
59	P883 DEVELOPMENT AND VALIDATION OF A POLYCYSTIC LIVER DISEASE COMPLAINT SPECIFIC ASSESSMENT (POLCA). Journal of Hepatology, 2014, 60, S368.	3.7	0
60	Safety and efficacy of different lanreotide doses in the treatment of polycystic liver disease: pooled analysis of individual patient data. Alimentary Pharmacology and Therapeutics, 2013, 38, 397-406.	3.7	38
61	Aortic calcifications and arterial stiffness as predictors of cardiovascular events in incident renal transplant recipients. Transplant International, 2013, 26, 973-981.	1.6	36
62	Measuring the glomerular filtration rate in different age groups using iohexol, the protocol from the Belgian iohexol study. Clinical Biochemistry, 2013, 46, 31-36.	1.9	6
63	Chronic Histological Damage in Early Indication Biopsies Is an Independent Risk Factor for Late Renal Allograft Failure. American Journal of Transplantation, 2013, 13, 86-99.	4.7	56
64	Combined Kidney and Intestinal Transplantation in Patients With Enteric Hyperoxaluria Secondary to Short Bowel Syndrome. American Journal of Transplantation, 2013, 13, 1910-1914.	4.7	19
65	Intrarenal Resistive Index after Renal Transplantation. New England Journal of Medicine, 2013, 369, 1797-1806.	27.0	185
66	POST-STREPTOCOCCAL GLOMERULONEPHRITIS: NOT AN EXTINCT DISEASE!. Acta Clinica Belgica, 2013, 68, 215-217.	1.2	2
67	Renal Clearance and Intestinal Generation of p-Cresyl Sulfate and Indoxyl Sulfate in CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1508-1514.	4.5	93
68	Diabetic Muscle Infarction: A Rare Cause of Acute Limb Pain in Dialysis Patients. Case Reports in Nephrology, 2013, 2013, 1-6.	0.4	5
69	Reasons for dose reduction of mycophenolate mofetil during the first year after renal transplantation and its impact on graft outcome. Transplant International, 2013, 26, 813-821.	1.6	51
70	Residual renal function is an independent determinant of serum FGF-23 levels in dialysis patients. Nephrology Dialysis Transplantation, 2012, 27, 2017-2022.	0.7	36
71	Impact of Vascular Calcification on Corrected QT Interval at the Time of Renal Transplantation. American Journal of Nephrology, 2012, 35, 24-30.	3.1	13
72	Cardiovascular complications in CKD 5D. Nephrology Dialysis Transplantation, 2012, 27, ii227-ii251.	0.7	0

#	Article	IF	Citations
73	1395 THE REDUCTION IN LIVER VOLUME IN POLYCYSTIC LIVER DISEASE WITH LANREOTIDE IS DOSE DEPENDENT AND IS MOST PRONOUNCED IN PATIENTS WITH THE HIGHEST LIVER VOLUME. Journal of Hepatology, 2012, 56, S547.	3.7	4
74	Multimodality Imaging of Giant Coronary Artery Aneurysms in Immunoglobulin G4-Related Sclerosing Disease. Journal of the American College of Cardiology, 2012, 59, e27.	2.8	15
75	Mineral metabolism in renal transplant recipients discontinuing cinacalcet at the time of transplantation: a prospective observational study. Clinical Transplantation, 2012, 26, 393-402.	1.6	36
76	Urea and Uremic Solutes: How Does Peritoneal Dialysis Work?. Seminars in Nephrology, 2011, 31, 127-137.	1.6	6
77	Prevalence and determinants of anemia in the immediate postkidney transplant period. Transplant International, 2011, 24, 1208-1215.	1.6	19
78	Systematic review: the pathophysiology and management of polycystic liver disease. Alimentary Pharmacology and Therapeutics, 2011, 34, 702-713.	3.7	79
79	Reduction in Protein-Bound Solutes Unacceptable as Marker of Dialysis Efficacy during Alternate-Night Nocturnal Hemodialysis. American Journal of Nephrology, 2011, 34, 226-232.	3.1	22
80	Warning: the unfortunate end of p-cresol as a uraemic toxin. Nephrology Dialysis Transplantation, 2011, 26, 1464-1467.	0.7	86
81	Fluctuations of haemoglobinaemia in chronic haemodialysis patients. Acta Clinica Belgica, 2011, 66, 123-8.	1.2	4
82	Troponin I Is a Predictor of Acute Cardiac Events in the Immediate Postoperative Renal Transplant Period. Transplantation, 2010, 89, 341-346.	1.0	11
83	Maintenance Immunosuppressive Agents as Risk Factors for BK Virus Nephropathy: The Need for True Drug Exposure Measurements. Transplantation, 2010, 89, 1296-1297.	1.0	6
84	Authors' Reply: Troponin I and Cardiovascular Events in Transplant Patients. Transplantation, 2010, 90, 339-340.	1.0	0
85	Fibroblast Growth Factor-23 in Early Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1268-1276.	4.5	96
86	Educating end-stage renal disease patients on dialysis modality selection: clinical advice from the European Renal Best Practice (ERBP) Advisory Board. Nephrology Dialysis Transplantation, 2010, 25, 1757-1759.	0.7	88
87	Educating end-stage renal disease patients on dialysis modality selection. CKJ: Clinical Kidney Journal, 2010, 3, 225-233.	2.9	24
88	Measuring Total Blood Calcium Displays a Low Sensitivity for the Diagnosis of Hypercalcemia in Incident Renal Transplant Recipients. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 2085-2092.	4.5	23
89	p-Cresol and Cardiovascular Risk in Mild-to-Moderate Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1182-1189.	4.5	265
90	p-Cresyl Sulfate and Indoxyl Sulfate in Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1932-1938.	4.5	142

#	Article	IF	Citations
91	Uremic toxins originating from colonic microbial metabolism. Kidney International, 2009, 76, S12-S19.	5.2	349
92	Calcium Metabolism in the Early Posttransplantation Period. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 665-672.	4.5	72
93	Localization, Etiology and Impact of Calcium Phosphate Deposits in Renal Allografts. American Journal of Transplantation, 2009, 9, 2470-2478.	4.7	46
94	Immunogenicity of a Standard Trivalent Influenza Vaccine in Patients on Long-term Hemodialysis: An Open-Label Trial. American Journal of Kidney Diseases, 2009, 54, 77-85.	1.9	63
95	Sodium octanoate to reverse indoxyl sulfate and p-cresyl sulfate albumin binding in uremic and normal serum during sample preparation followed by fluorescence liquid chromatography. Journal of Chromatography A, 2009, 1216, 4684-4688.	3.7	65
96	Removal of the Uremic Retention Solute pâ€Cresol Using Fractionated Plasma Separation and Adsorption. Artificial Organs, 2008, 32, 214-219.	1.9	60
97	A Review of Albumin Binding in CKD. American Journal of Kidney Diseases, 2008, 51, 839-850.	1.9	99
98	Influenza Vaccination Is Efficacious and Safe in Renal Transplant Recipients. American Journal of Transplantation, 2008, 8, 332-337.	4.7	139
99	Calcium Requirements after Parathyroidectomy in Patients with Refractory Secondary Hyperparathyroidism. Nephron Clinical Practice, 2008, 110, c80-c85.	2.3	51
100	A single-centre study of adjuvant cidofovir therapy for BK virus interstitial nephritis (BKVIN) in renal allograft recipients. Journal of Antimicrobial Chemotherapy, 2008, 63, 417-419.	3.0	29
101	Early clinical assessment of glucose metabolism in renal allograft recipients: diagnosis and prediction of post-transplant diabetes mellitus (PTDM). Nephrology Dialysis Transplantation, 2008, 23, 2033-2042.	0.7	65
102	AA amyloidosis due to chronic oxalate arthritis and vasculitis in a patient with secondary oxalosis after jejunoileal bypass surgery. Nephrology Dialysis Transplantation, 2008, 23, 3362-3364.	0.7	5
103	Recovery of Hyperphosphatoninism and Renal Phosphorus Wasting One Year after Successful Renal Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 1829-1836.	4.5	124
104	Free p-cresol is associated with cardiovascular disease in hemodialysis patients. Kidney International, 2008, 73, 1174-1180.	5.2	276
105	Fatal right-sided endocarditis due toAspergillusin a kidney transplant recipient. Medical Mycology, 2007, 45, 565-568.	0.7	13
106	High Rate of Charcot Foot Attacks Early After Simultaneous Pancreas???Kidney Transplantation. Transplantation, 2007, 83, 245-246.	1.0	35
107	Response to â€˜Superior dialytic clearance of Î²2-microglobulin and p-cresol by high-flux hemodialysis as compared to peritoneal dialysisâ€™. Kidney International, 2007, 71, 467-468.	5.2	1
108	Another devastating complication of the Schnitzler syndrome: AA amyloidosis. British Journal of Dermatology, 2007, 158, 071018053044006-???.	1.5	29

#	Article	IF	Citations
109	Major Coagulation Disturbances During Fractionated Plasma Separation and Adsorption. American Journal of Transplantation, 2007, 7, 2195-2199.	4.7	65
110	Heparin-Coated Polyacrylonitrile Membrane Versus Regional Citrate Anticoagulation: A Prospective Randomized Study of 2 Anticoagulation Strategies in Patients at Risk of Bleeding. American Journal of Kidney Diseases, 2007, 49, 642-649.	1.9	68
111	The influence of inulin on the absorption of nitrogen and the production of metabolites of protein fermentation in the colon. British Journal of Nutrition, 2006, 96, 1078-1086.	2.3	53
112	Prometheus Versus Molecular Adsorbents Recirculating System: Comparison of Efficiency in Two Different Liver Detoxification Devices. Artificial Organs, 2006, 30, 276-284.	1.9	105
113	Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients. Kidney International, 2006, 69, 1081-1087.	5.2	340
114	Acarbose treatment lowers generation and serum concentrations of the protein-bound solute p-cresol: A pilot study. Kidney International, 2006, 70, 192-198.	5.2	63
115	Superior dialytic clearance of Î²2-microglobulin and p-cresol by high-flux hemodialysis as compared to peritoneal dialysis. Kidney International, 2006, 70, 794-799.	5.2	93
116	Comparison of peritoneal dialysis and haemodialysis after renal transplant failure. Nephrology Dialysis Transplantation, 2006, 21, 1669-1674.	0.7	51
117	Time Profiles of Peritoneal and Renal Clearances of Different Uremic Solutes in Incident Peritoneal Dialysis Patients. American Journal of Kidney Diseases, 2005, 46, 512-519.	1.9	77
118	The molecular adsorbent recycling system (MARS) and transmembrane transport of albumin-bound toxins. Liver Transplantation, 2005, 11, 853-854.	2.4	10
119	Validation of lactose[15N,15N]ureide as a tool to study colonic nitrogen metabolism. American Journal of Physiology - Renal Physiology, 2005, 288, G994-G999.	3.4	20
120	Gas Chromatographicâ€“Mass Spectrometric Analysis for Measurement of p-Cresol and Its Conjugated Metabolites in Uremic and Normal Serum. Clinical Chemistry, 2005, 51, 1535-1538.	3.2	172
121	Detoxifying Capacity and Kinetics of Prometheus^{Â®} â€“ A New Extracorporeal System for the Treatment of Liver Failure. Blood Purification, 2005, 23, 349-358.	1.8	82
122	Improving Removal of Protein-Bound Retention Solutes. , 2005, 149, 175-184.		3
123	Impairment of small intestinal protein assimilation in patients with end-stage renal disease: extending the malnutrition-inflammation-atherosclerosis concept. American Journal of Clinical Nutrition, 2004, 80, 1536-1543.	4.7	62
124	Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study. Nephrology Dialysis Transplantation, 2004, 19, 1281-1287.	0.7	273
125	Removal of the protein-bound solute p-cresol by convective transport: A randomized crossover study. American Journal of Kidney Diseases, 2004, 44, 278-285.	1.9	155
126	Validation of a New Test Meal for a Protein Digestion Breath Test in Humans. Journal of Nutrition, 2004, 134, 806-810.	2.9	21

#	Article	IF	Citations
127	Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relation with uremic symptoms. Kidney International, 2003, 64, 2238-2243.	5.2	178
128	Evidence for impaired assimilation of protein in chronic renal failure. Kidney International, 2003, 64, 2196-2203.	5.2	107
129	13C-breath tests in peritoneal dialysis patients. European Journal of Gastroenterology and Hepatology, 2003, 15, 931-932.	1.6	3
130	Detoxifying Capacity and Kinetics of the Molecular Adsorbent Recycling System. Blood Purification, 2003, 21, 244-252.	1.8	44